Trial Information

Summary: CTSU/ECOG E2805: A Randomized, Double-Blind Phase III Trial of Adjuvant Sunitinib versus Sorafenib versus Placebo in Resected Renal Cell Carcinoma

You are being asked to take part in this research study because you have kidney cancer (renal cell cancer, RCC) which has just been removed or is about to be removed, and you are thought to be at high risk for relapse (return of disease).  The purpose of this study is to determine if Sunitinib and/or Sorafenib can prevent recurrence of kidney cancer as compared to placebo (inactive agent).  This study will also evaluate overall survival and side effects in subjects receiving these treatments.  Researchers will also study tumor and blood specimens in the laboratory to find out whether biological and genetic differences in tumors are related to differences in response to treatment and to find out the effects of the different treatments on the cancer genes.  Your participation in this study is expected to last 54 weeks (about 1 year) for treatment and your condition will be followed indefinitely.

Patient Inclusion/Exclusion Criteria:

- See http://clinicaltrials.coh.org for additional information.

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Trial listings updated: July 7, 2008 at 2:39:54 PM